title: [Evaluation of transfusion hemochromatosis prevalence, SFVTT-01 study: preliminary results of the SFVTT working group].
abstract: BACKGROUND
  Although notification of post-transfusion hemosiderosis is mandatory since 1994 among the French hemovigilance network, it is so far largely under reported.
  
  
  METHODS
  We screened 42,443 patients hospitalized for blood diseases in France in 2009 and 2010 and determined which patients had received more than 20 PRC. Among them, we selected those having at least one measure of serum ferritin, and subsequently those which ferritin was greater than or equal to 1000 ng/mL.
  
  
  RESULTS
  Three thousand eight hundred and twelve patients (9%) received more than 20 PRC, 1935 (4.5%) had a ferritin assay, which was increased in 1216 patients (2.9%). Eight hundred and eighty-one patients underwent an hemovigilance report form. Forty-nine percent had low-risk myelodysplasia or acute leukemia, 7% hemoglobinopathies. Hemosiderosis was asymptomatic for 680 patients (77%), serious 188 (88%) and life-threatening for 11 (1%). Two patients died of terminal heart failure. The most severe hemosiderosis (≥ grade 2) were low-risk myelodysplasia and idiopathic aplastic anemia. Ninety-two percent of thalassemia patients and 46% of sickle cell anemia patients received an iron chelator. For low-risk myelodysplastic syndromes and idiopathic aplastic anemia, 228 of the 317 patients whose treatment is known and who could benefit from iron chelation (72%) have not received it.
  
  
  CONCLUSIONS
  These results encourage seeking optimal transmission of information (over 20 CGR) to the clinician, and prolonging hemovigilance action towards a more comprehensive statement of post-transfusion hemochromatosis.
authors.affiliation: Unité de sécurité transfusionnelle et d'hémovigilance, centre hospitalier régional d'Orléans, hôpital de la Source, 14, avenue de l'Hôpital, 45067 Orléans cedex 2, France. Electronic address: silvana.leo-kodeli@chr-orleans.fr.
authors.forename: S
authors.initials: S
authors.lastname: Leo-Kodeli
authors.affiliation: Agence régionale de santé Lorraine, immeuble les Thiers, 4, rue Piroux, 54036 Nancy cedex, France.
authors.forename: P
authors.initials: P
authors.lastname: Renaudier
authors.affiliation: Unité d'hémovigilance, hôpital Sainte-Marguerite, Assistance publique-Hôpitaux de Marseille, 244, boulevard Sainte-Marguerite, 13274 Marseille cedex 09, France.
authors.forename: B
authors.initials: B
authors.lastname: Lassale
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D058731:Blood Safety; D015913:Chelation Therapy / Q000706:statistics & numerical data; D002648:Child; D002675:Child, Preschool; D003430:Cross-Sectional Studies; D018563:Disease Notification; D005260:Female; D005293:Ferritins / Q000097:blood; D005602:France / Q000453:epidemiology; D006333:Heart Failure / Q000209:etiology; D006453:Hemoglobinopathies / Q000150:complications / Q000628:therapy; D006486:Hemosiderosis / Q000097:blood / Q000453:epidemiology* / Q000209:etiology / Q000628:therapy; D006801:Humans; D007502:Iron Chelating Agents / Q000627:therapeutic use; D007938:Leukemia / Q000150:complications / Q000628:therapy; D008297:Male; D008875:Middle Aged; D009190:Myelodysplastic Syndromes / Q000150:complications / Q000628:therapy; D012189:Retrospective Studies; D065227:Transfusion Reaction; D055815:Young Adult
chemical_list: D007502:Iron Chelating Agents; D005293:Ferritins
keywords: Hemosiderosis; Hemovigilance; Hémosidérose; Hémovigilance; Iron overload; Surcharge en fer; Transfusion